Table 4. . Updates in hepatocellular carcinoma selective internal radiation.
Study | Trial | Phase | Number of patients | Child–Pugh class | Line of therapy | Intervention | Median OS | RR (%) | Ref. |
---|---|---|---|---|---|---|---|---|---|
Vilgrain et al. | SARAH | III | 459 | A/B | Failed 2 + rounds of chemoembolization | SIRT (Y-90) vs sorafenib | 8.0 vs 9.9 (months) (p = 0.179) | 19.0 vs 11.6 (p = 0.042) | [50] |
Pierce et al. | SIRveNIB | III | 360 | A/B | ≤2 rounds of chemoembolization | SIRT (Y-90) vs sorafenib | 8.8 vs 10.0 (months) (p = 0.203) | 16.5 vs 1.7 (p < 0.001) | [51] |
Meyer et al. | TACE 2 | III | 313 | A | 1 | TACE + sorafenib vs TACE + placebo | 631 vs 598 (days) (p = 0.57) | 36 vs 31 (p-value not provided) | [53] |
OS: Overall survival; RR: Response rate; SIRT: Selective internal radiation therapy; TACE: Transarterial chemoembolization.